Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 3-10

  Chang, Alex ^a  

^a Johns Hopkins Singapore   (Singapore)

Author keywords

III Tubulin; Biomarkers; Chemoresistance; Chemotherapy; Epothilones; NSCLC

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA TUBULIN; CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IRINOTECAN; IXABEPILONE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; PACLITAXEL; PICOPLATIN; PLATINUM DERIVATIVE; SAGOPILONE; SATRAPLATIN; TAU PROTEIN; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ALGORITHM; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EXPOSURE; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL SPECIALIST; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS;

EID: 78650236850     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.08.022     Document Type: Review

References (79)

1. Horner M.J., Ries L.A.G., Krapcho M., Neyman N., Aminou R., Howlader N., et al. SEER cancer statistics review, 1975-2006 2009, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA Cancer J Clin 2010, [Epub ahead of print].
3. Parkin D.M., Bray F., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
4. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
5. Jemal A., Thun M.J., Ries L.A.G., Howe H.L., Weir H.K., Center M.M., et al. Annual report to the Nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Non-small cell lung cancer. V2.2009. Available at: ; 2009 [accessed May 26]. http://www.nccn.org/.
7. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J., et al. The International Adjuvant Lung Cancer Trial Collaborative Group: cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004, 350:351-360.
8. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzáles-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialists Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
9. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
10. Chien A.J., Moasser M.M. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 2008, 35(Suppl. 2):S1-S14.
11. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008, 34:378-390.
12. Gatti L., Zunino F. Overview of tumor cell resistance mechanisms. Methods Mol Med 2005, 111:127-148.
13. D'Amato T.A., Landreneau R.J., McKenna R.J., Santos R.S., Parker R.J. Prevalence of in vitro extreme chemotherapy resistance in resected non small-cell lung cancer. Ann Thorac Surg 2006, 81:440-447.
14. Matsumoto Y., Oka M., Sakamoto A., Narasaki F., Fukuda M., Takatani H., et al. Enhanced expression of metallothioneins in human non-small-cell lung carcinomas following chemotherapy. Anticancer Res 1997, 17:3777-3780.
15. Hida T., Ariyoshi Y., Kuwabara M., Sugiura T., Takahashi T., Takahashi T., et al. Glutathione S-trasnferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn J Clin Oncol 1993, 23:14-19.
16. Azuma K., Sasada T., Kawahara A., Takamori S., Hattori S., Ikeda J., et al. Expression of ERCC1 and class III βIII tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64:326-333.
17. Azuma K., Sasada T., Kawahara A., Hattori S., Kinoshita T., Takamori S., et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009, 64:565-573.
18. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
19. Schettino C., Bareschino M.A., Maione P., Rossi A., Ciardiello F., Gridelli C. The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics 2008, 9:252-262.
20. Li J., Li Z.N., Du Y.J., Li X.Q., Bao Q.L., Chen P. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer 2009, 10(November (6)):414-421.
21. Vilmar A.C., Santoni-Rugiu E., Sørensen J.B. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010, [Epub ahead of print].
22. Vilmar A., Sørensen J.B. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 2009, 64(May (2)):131-139. [Epub 2008 September 19].
23. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2(October (10)):902-906.
24. Belper G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
25. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004, 10:1318-1325.
26. Simon G.R., Sharma S., Cantor A., Smith P., Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127:978-983.
27. Al Omari A., Murry D.J., Smith B.J., Clamon G., Bhatia S., Vaena D. Genetic variability in DNA repair and clinical outcome in stage III non-small cell lung cancer (NSCLC) treated with concurrent platinum-based chemoradiation. J Clin Oncol 2009, 27(Suppl.). [abstract e14621].
28. Rosell R., Skrzpski M., Jassem E., Taron M., Bartolucci R., Sanchez J.J., et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007, 2:e1129.
29. Rosell R., Perez-Roca L., Sanchez J.J., Cobo M., Moran T., Chaib I., et al. Customized treatment of non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PloS ONE 2009, 4:e5133.
30. Andrews P.A., Jones J.A., Varki N.M., Howell S.B. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of ovarian carcinoma. Cancer Commun 1990, 2:93-100.
31. Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991, 87:772-777.
32. Crul M., van Waardenburg R.C., de Jong L.A., van Eijndhoven M.A., Pluim D., Beijnen J.H., et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003, 65:275-282.
33. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002, 2:1-17.
34. Sève P., Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 2008, 9:168-175.
35. Burkhart C.A., Kavallaris M., Horwitz S.B. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001, 1471:1-9.
36. Wehbe H., Kearney C.M., Pinney K.G. Combretastatin A-4 resistance in H640 human lung carcinomas demonstrates distinctive alterations in β-tubulin isotype expression. Anticancer Res 2005, 25:3865-3870.
37. Gan P.P., Pasquier R.M.K. Class III (beta)-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007, 67:9356-9363.
38. Kavallaris M., Burkhart C.A., Horwitz S.B. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999, 80:1020-1025.
39. McCarroll J.A., Gan P.P., Kavallaris M. Novel role of (III tubulin in tumorigenesis and drug sensitivity in non-small cell lung cancer. Proceedings of the 100th annual meeting of the american association for cancer research 2009, [abstract 3337].
40. Dumontet C., Isaac S., Souquet P.J., Bejui-Thivolet F., Pacheco Y., Peloux N., et al. Expression of class III β-tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005, 92:E25-E30.
41. Rosell R., Scagliotti G., Danenberg K.D., Lord R.V., Bepler G., Novello S., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003, 22:3548-3552.
42. Sève P., Issac S., Trédan O., Souquet P.J., Pachéco Y., Pérol M., et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005, 11:5481-5486.
43. Sève P., Mackey J., Isaac S., Trédan O., Souquet P.J., Pérol M., et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005, 4:2001-2007.
44. Sève P., Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005, 5:73-88.
45. Sève P., Lai R., Ding K., Winton T., Butts C., Mackey J., et al. Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007, 13:994-999.
46. Sève P., Reiman T., Isaac S., Trillet-Lenoir V., Lafanéchère L., Sawyer M., et al. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 2008, 28(2B):1161-1167.
47. Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K., et al. Establishment of camptothecin analogue (CPT-11)-resistance cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990, 50:5919-5924.
48. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246:1046-1048.
49. Saleem A., Edwards T.K., Rasheed Z., Rubin E.H. Mechanisms of resistance to camptothecins. Ann N Y Acad Sci 2000, 922:46-55.
50. Xu Y., Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002, 13:1841-1851.
51. Boukovinas I., Papadaki C., Mendez P., Taron M., Mavroudis D., Koutsopoulos A., et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 2008, 3:e3695.
52. Belper G., Li X., Schell M., Zheng Z., Boulware D., Obasaju C.K., et al. Predictive value of RRM1 and ERCC1 protein levels in a prospective community-based trial of gemcitabine/carboplatin versus gemcitabine alone. J Clin Oncol 2008, 26(Suppl.):8033. [abstract].
53. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17:1818-1825.
54. Kim S.O., Jeong J.Y., Kim M.R., Cho H.J., Ju J.Y., Kwon Y.S., et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008, 14:3083-3088.
55. Edelman M.J. Novel cytotoxic agents for non-small cell lung cancer. J Thorac Oncol 2006, 1:752-755.
56. Dumontet C., Jordan M.A., Lee F.F.Y. Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009, 8:17-25.
57. Tsao M.S., Aviel-Ronen S., Ding K., Lau D., Liu N., Sakurada A., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5240-5247.
58. Mimori K., Sadanaga N., Yoshikawa Y., Ishikawa K., Hashimoto M., Tanaka F., et al. Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer 2006, 94:1894-1897.
59. Smoter M., Grala B., Bodnar C., Szczylik C. Tau expression as a predictive marker in ovarian cancer patients (pts) treated with platinum/paclitaxel chemotherapy. J Clin Oncol 2009, 27(Suppl.):5529. [abstract].
60. Tanaka S., Nohara T., Iwamoto M., Sumiyoshi K., Kimura K., Takahashi Y., et al. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 2009, 64:341-346.
61. Simon G., Sharma A., Li X., Hazelton T., Walsh F., Williams C., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:2741-2746.
62. Chiappori A., Simon G., Williams C., Haura E., Rocha-Lima C., Wagner H., et al. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 2005, 68:382-390.
63. Sato Y., Yamamoto N., Kunitoh H., Ohe Y., Katori N., Sawada J., et al. Genome-wide association scan detected candidate polymorphisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel. J Clin Oncol 2009, 27(Suppl.):8031. [abstract].
64. Eckardt J.R., Bentsion D.L., Lipatov O.N., Polyakov I.S., Mackintosh F.R., Karlin D.A., et al. Phase II study of picoplatin as second-line therapy for patients with small cell lung cancer. J Clin Oncol 2009, 27:2046-2051.
65. Ciuleanu T., Samarzjia M., Demidchik Y., Beliakouski V., Rancic M., Bentsion D.L., et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010, 28(15s). [Suppl; abstr 7002].
66. Mauer A.M., Cohen E.E., Ma P.C., Kozloff M.F., Schwartzberg L., Coates A.I., et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:631-636.
67. Vansteenkiste J., Lara P.N., Le Chevalier T., Breton J.L., Bonomi P., Sandler A.B., et al. Phase II clinical trial of the epothilone B analog ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007, 25:3448-3455.
68. Sanchez J.M., Mellemgaard A., Perry M., Zatloukal P., Hamm J., Belani C.P., et al. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/II trial. J Clin Oncol 2006, 24(Suppl.):7104. [abstract].
69. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zaharevitz D., Bollbuck B., et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000, 97:2904-2909.
70. Nettles J.H., Li H., Cornett B., Krahn J.M., Snyder J.P., Downing K.H. The binding mode of epothilone A on alpha-, beta-tubulin by electron crystallography. Science 2004, 305:866-869.
71. Verrils N.M., Flemming C.L., Liu M., Ivery M.T., Cobon G.S., Norris M.D., et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interaction. Chem Biol 2003, 10:597-607.
72. Mozzetti S., Iantomasi R., De Maria I., Prislei S., Mariani M., Camperchioli A., et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008, 68:10197-10204.
73. Magnani N., Ortuso F., Soro S., Alcaro S., Tramontano A., Botta M. The βI/βIII-tubulin isoforms and their complexes with antimitotic agents. FEBS J 2006, 273:3301-3310.
74. Jordan MA, Miller H, Ray A, Banerjee A, Manna T, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin has altered β-tubulin expression and is sensitive to ixabepilone. Presented at the 97th AACR Annual Meeting. Washington, District of Colombia, April 1-5; 2006 [abstract LB-280].
75. Belani C.P., Brodowicz T., Ciuleanu T., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(Suppl.):CRA8000. [abstract].
76. Brugger W., Triller N., Blasinska-Morawiec M., Curescu S., Sakalauskas R., Manikhas G., et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009, 27(Suppl.):8020. [abstract].
77. Mok T., Wu Y.L., Thongprasert S., Yang C.-H., Chu D.-T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009, 361:1018-1020.
78. Kim E.S., Hirsch V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
79. Thatcher N., Chang A., Parikh P., Baildam A., Campbell I. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.